Samuels L E, Holmes E C, Thomas M P, Entwistle J C, Morris R J, Narula J, Wechsler A S
MCP Hahnemann University, Department of Cardiothoracic Surgery, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA.
Ann Thorac Surg. 2001 Mar;71(3 Suppl):S67-72; discussion S82-5. doi: 10.1016/s0003-4975(00)02644-8.
Mechanical circulatory assist industries have developed ventricular assist devices (VAD) for short-, intermediate-, and long-term use. The purpose of this report is to describe the progress made with the ABIOMED Biventricular System (BVS) 5000 (ABIOMED, Inc, Danvers, MA) short-term VAD.
From June 1994 through August 2000, all cardiogenic shock patients who required short-term mechanical assist were supported with the ABIOMED BVS 5000. Insertion criteria included any condition that may potentially result in cardiac recovery. A formal algorithm for timing of insertion was established to standardize implantation criteria.
A total of 45 patients were supported at Hahnemann University Hospital, Philadelphia, PA. There were 26 male and 19 female patients, with a mean age of 57.9 years (range 33 to 80 years). Devices were inserted for postcardiotomy shock in 36 patients (80%) and precardiotomy shock in 9 patients (20%). The average duration of support was 8.3 days (range 1 to 31 days). Overall, there were 22 (49%) patients weaned from support and 14 (31%) discharged from the hospital. For patients in whom the device was implanted in accordance with an established protocol (group A), the wean and discharge rates were 60% and 43%, respectively. The most common morbidities included bleeding and adverse neurologic events.
The ABIOMED BVS 5000 VAD continues to be a valuable form of short-term mechanical assist for acute cardiogenic shock. The formation of a uniform VAD insertion algorithm has helped to standardize protocols in management.
机械循环辅助行业已开发出用于短期、中期和长期使用的心室辅助装置（VAD）。本报告的目的是描述ABIOMED双心室系统（BVS）5000（ABIOMED公司，马萨诸塞州丹弗斯）短期VAD所取得的进展。
从1994年6月至2000年8月，所有需要短期机械辅助的心源性休克患者均采用ABIOMED BVS 5000进行支持治疗。植入标准包括任何可能导致心脏恢复的情况。建立了正式的植入时机算法以规范植入标准。
宾夕法尼亚州费城哈内曼大学医院共为45例患者提供了支持。其中男性26例，女性19例，平均年龄57.9岁（范围33至80岁）。36例患者（80%）因心脏术后休克植入装置，9例患者（20%）因心脏术前休克植入装置。平均支持时间为8.3天（范围1至31天）。总体而言，22例患者（49%）成功脱机，14例患者（31%）出院。对于按照既定方案植入装置的患者（A组），脱机和出院率分别为60%和43%。最常见的并发症包括出血和不良神经事件。
ABIOMED BVS 5000 VAD仍然是急性心源性休克短期机械辅助的一种有价值的形式。统一的VAD植入算法的形成有助于规范管理方案。
